
SOCMA Raises Concerns about Toxic-Substances Reform Bill
The Society of Chemical Manufacturers and Affiliates is raising concerns over a recently introduced bill in the US Senate, which seeks to reform the Toxic Substances Control Act.
The Society of Chemical Manufacturers and Affiliates (SOCMA) issued a
Sen. Frank Lautenberg (D-NJ), who chairs the Senate Subcommittee on Superfund, Toxics and Environmental Health, introduced the Safe Chemicals Act of 2010 on Apr. 15, 2010. The bill would “require safety testing of all industrial chemicals and puts the burden on industry to prove that chemicals are safe in order stay on the market,” according to a
SOCMA represents contract manufacturers, including producers of active pharmaceutical ingredients and intermediates. Certain substances such as food, drugs, cosmetics, and pesticides are generally excluded from TSCA, but TSCA applies to approximately 83,000 chemicals, according to EPA. Although SOCMA agrees that TSCA should be reformed, it asserts that the new bill would be burdensome, particularly for small chemical manufacturers, and that the time and cost of implementation would negatively affect innovation.
“We are pleased to see that this bill makes an effort to address the need to prioritize chemicals, reduce animal testing, share information with state governments, and protect our country’s most vulnerable groups, including children,” according to a SOCMA statement. "However, the Safe Chemicals Act overreaches in its attempt to impose a new approach to regulating chemicals. The requirement that no less than 300 chemical substances be on the priority list at any given time is overly prescriptive. We have serious reservations with the minimum data-set requirement and extending it to all new uses of existing chemicals. We also have concerns with the expansion of the safety standard to industrial chemicals. This would create major challenges for SOCMA members, many of whom manufacture intermediates for which there may be limited exposures and many possible uses that are sometimes unknown to the manufacturer.” SOCMA added “any enhancement to TSCA should consider how the costs and delays associated with increased data submission requirements could impair the industry’s ability to innovate or jeopardize the sustainability of the chemical industry.”
SOCMA is urging Congress to consult with manufacturing stakeholders during the consideration and review of the new bill. “We look forward to further educating Congress about our concerns and impacts of this bill on our industry."
SOCMA has taken an active part in the TSCA reform debate. In a
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





